Plain-English translation of NCT07390955 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new HIV prevention approach using lab-made antibodies called ePGT121v1-LS, which are designed to target and neutralize the HIV virus. Researchers will give this medication alone or in combination with two other antibodies, either through an IV line into your vein or as injections under your skin. The study will check whether the treatment is safe, how your body processes it, and how well it protects against HIV.
Current HIV prevention methods like daily pills have limitations—some people forget to take them, and the virus can develop resistance. This medication represents a new approach: long-acting antibodies that could provide protection with fewer doses and potentially work even if the virus tries to evade it.
You likely qualify if…
You likely don't qualify if…
Depending on which group you are assigned to, you will either receive the medication through an IV infusion or as under-the-skin injections at one or two visits spaced weeks to months apart. You will attend follow-up clinic visits to have your blood checked, report any side effects, and have your body's response to the medication measured. The total time commitment ranges from 6 months to 1 year of scheduled visits.
AI-generated summary from trial data · Jul 16, 2026 · Not medical advice
United States